Wegovy Peptide Market Trends: Brand Competition, Efficacy Data, and Supply Chain Insights
Published: 12 7 月, 2026 21:14
Author: Andreas Mercier
Abstract: The Wegovy (semaglutide) peptide market is dominated by Novo Nordisk, with clinical trials showing 15% average weight loss versus 2.4% for placebo. Brand competition intensifies as Eli Lilly’s tirzepatide (Mounjaro) achieves 22.5% efficacy. Supply chain bottlenecks persist due to GMP-certified API scarcity and cold-chain logistics demands (2-8°C). Key differentiators include dosing regimens (weekly vs. daily) and purity thresholds (>99% for injectables). Market trends indicate a shift toward oral formulations and biosimilars, with regulatory compliance (FDA/EMA) critical for market access.